BillionToOne

Performance

About BillionToOne

BillionToOne is a molecular diagnostics company focused on advancing prenatal screening and liquid biopsy through proprietary single-molecule detection. Their UNITY Complete non-invasive prenatal test uses cfDNA to assess fetal risk for recessive conditions and aneuploidy from a maternal blood sample, enabling early prenatal insights. In oncology, their Northstar tests guide therapy selection and monitor treatment response through pan-cancer liquid biopsy tests. The company operates in the United States with accreditation foundations in California, including Menlo Park, and markets a range of products spanning prenatal and cancer diagnostics.